TABLE 1.
Bone marrow specimen description
| Specimen ID | Age/Sex | Disease * | Subtype | Prior Lines of Therapy | Latest line of treatment | Cytogenetic Risk † |
|---|---|---|---|---|---|---|
| PCD1020 | 66/F | MM | IgG‐K | 3 | Velcade maintenance | High Risk |
| PCD1201 | 66/F | MM | IgG‐L | 3 | RV maintenance(off therapy for 40mo) | High Risk |
| PCD1218 | 52/M | MM | IgG‐L | 5 | Elo‐Rd | High Risk |
| PCD1300 | 57/M | MM/PCL | IgA‐K | 3 | KRd followed by Mel200‐ASCT(off therapy for 13mo) | High Risk |
| PCD1421 | 59/M | MM | KLC | 3 | Velcade Maintenance(off therapy for 7mo) | High Risk |
| PCD1427 | 65/F | MM | IgG‐L | 3 | KRd‐Elo | Standard |
| PCD1441 | 71/M | MM | LLC | 4 | KRd‐Elo | Standard |
| PCD1447 | 68/F | MM | IgG‐K | 4 | CarCy(off therapy for 12mo) | High Risk |
| PCD1527 ‡ | 54/F | MM | KLC | 3 | Dara‐Vd | High Risk |
| PCD1542 | 53/M | MM | IgG‐K | 6 | Pom‐Dex | Standard |
Abbreviations: MM: multiple myeloma Myeloma, PCL: plasma cell leukemia. Bor/V: Bortezomib, Car/K: Carlfilzomib, Dara: daratumumab, Dex/d: dexamethasone, Elo Elotuzimab, Mel200‐AST: high‐dose Melphalan and autologous stem cell transplant, Pom: pomalidamide R: Revlimid,
*
All patients were relapsing at the time of bone marrow aspirate collection.
†
[As per IWMG criteria] Standard Risk: normal cytogenetics, hyperdiploidy, or t(11;14); Intermediate Risk: [t(6;14), del 13, or others not in good or high risk; High Risk: del 17p, t(4;14), t(14;16), t(14;20), amplification 1q21, complex cytogenetics, or hypodiploidy.
‡
Plasma cells from this BMMC specimen were CD38 negative.